A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

Mendeley Data2021-03-08 更新2026-04-09 收录

特应性皮炎病原检测

药代动力学

数据链接：

https://data.mendeley.com/datasets/ctdyb5zvs5 数据链接链接失效反馈

官方服务：

资源简介：

Author video for the article: Paller AS, Siegfried EC, et al. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2021;35(2):464-475.

创建时间：

2021-03-08

A phase 2, open-label study of single-dose dupilumab in children aged 6 months to &lt;6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

资源简介：

相关数据集

A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy